The role of immunohistochemistry in the diagnosis of poorly differentiated malignant neoplasms.

Abstract

The development and refinement of immunohistochemical methodologies over the past decade has had a major impact in many different areas of diagnostic pathology. The generation of increasing numbers of well-characterized polyclonal antisera and monoclonal antibodies directed to a variety of antigenic determinants has made the phenotyping of neoplasms a reality. The results of such immunohistochemical analyses have provided an important starting point for the further workup and management of patients with undifferentiated or poorly differentiated malignant neoplasms of unknown origin. It should also be apparent, however, that the results of immunohistochemical analyses in such clinical settings are subject to a large number of variables and that these procedures must be controlled rigorously. The results of extensive performance testing, particularly with new reagents, must be available in order to establish their specificities and sensitivities under different conditions of tissue fixation and processing. Such studies not only will establish more precise and reproducible diagnostic criteria but also will be important for the definition of new clinical and pathological entities and for the characterization of novel prognostic parameters.